Dihydromyricetin Alleviates Nonalcoholic Fatty Liver Disease and Its Associated Metabolic Syndrome by Inhibiting Endoplasmic Reticulum Stress in LDLR^−/− Mice Fed with a High-Fat and High-Fructose Diet

Figure 3

Visceral fat decrease in the DHM-treated LDLR^−/− mice: (a) body weight before and during the DHM challenge and ND or HFD feeding, (b) weight of adipose tissues; n = 8 per group and ^#, (c) hematoxylin and eosin (H&E) staining of epididymis fat; bar = 100 μm, (d) adipocyte size distribution in epididymis fat. ImageJ software was used for quantification. Distribution of adipocyte areas is shown in each column. Five mice with 200 adipocytes per mouse were analyzed for every distribution, (e) H&E staining of the retroperitoneal fat; bar = 100 μm, (f) adipocyte size distribution in retroperitoneal fat, (g) mRNA expression of genes in epididymis fat (n = 6 per group), and (h) mRNA expression of genes in the retroperitoneal fat (n = 6 per group). ^#Compared with the normal control group (ND); ^&compared with the control group (HFD); ^#/& and ^##/&&.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)